Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
Today, 5:05 AM
Guggenheim analyst Brad Canino reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $40 price target.
Scotiabank Maintains Sector Outperform on Oracle, Raises Price Target to $360
Today, 5:05 AM
Scotiabank analyst Patrick Colville maintains Oracle (NYSE:ORCL) with a Sector Outperform and raises the price target from $350 to $360.
JP Morgan Maintains Neutral on Herc Holdings, Raises Price Target to $140
Today, 5:05 AM
JP Morgan analyst Tami Zakaria maintains Herc Holdings (NYSE:HRI) with a Neutral and raises the price target from $127 to $140.
CIBC Maintains Neutral on Royal Gold, Raises Price Target to $250
Today, 5:05 AM
CIBC analyst Anita Soni maintains Royal Gold (NASDAQ:RGLD) with a Neutral and raises the price target from $225 to $250.
Barclays Maintains Equal-Weight on Lincoln National, Raises Price Target to $46
Today, 5:05 AM
Barclays analyst Alex Scott maintains Lincoln National (NYSE:LNC) with a Equal-Weight and raises the price target from $42 to $46.
Needham Initiates Coverage On Red Cat Holdings with Buy Rating, Announces Price Target of $17
Today, 5:05 AM
Needham analyst Austin Bohlig initiates coverage on Red Cat Holdings (NASDAQ:RCAT) with a Buy rating and announces Price Target of $17.
Galapagos NV Advances Cell Therapy Business Divestment Review; Expects Decision By November 5, 2025
Today, 5:05 AM
Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) and its Board of Directors today issued the following statement:On May 13, 2025, Galapagos announced that its Board of Directors
Applied DNA $58M PIPE Offerings Involves 4,730,178 Shares Of Common Stock And Common Warrants; A Cryptocurrency Offering Involving 3,334,471 Prefunded Warrants And Common Warrants; The Warrants In Both Offerings Have An Exercise Price Of $3.82 And A 5-Year Term
Today, 5:05 AM
Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Compan
SOS H1 Sales $89.595M Up From $60.514M YoY
Today, 5:05 AM
SOS (NYSE: SOS) reported $89.595 million in sales this quarter. This is a 48.06 percent increase over sales of $60.514 million the same period last year.